A Small-Molecule Activator of Sarco/Endoplasmic Reticulum Ca2+-ATPase Attenuates Cerebral Ischemia–Reperfusion Injury by Suppressing Endoplasmic Reticulum Stress and Apoptosis

IF 3.7 Q1 CHEMISTRY, MEDICINAL
Vikrant Rahi,  and , Ravinder K. Kaundal*, 
{"title":"A Small-Molecule Activator of Sarco/Endoplasmic Reticulum Ca2+-ATPase Attenuates Cerebral Ischemia–Reperfusion Injury by Suppressing Endoplasmic Reticulum Stress and Apoptosis","authors":"Vikrant Rahi,&nbsp; and ,&nbsp;Ravinder K. Kaundal*,&nbsp;","doi":"10.1021/acsptsci.5c00151","DOIUrl":null,"url":null,"abstract":"<p >Calcium (Ca<sup>2+</sup>) homeostasis is critical for neuronal survival and function, which is regulated by a network of Ca<sup>2+</sup>-handling proteins. Among these, the sarco/endoplasmic reticulum calcium ATPase (SERCA) pump, located on the SR/ER membrane, plays a pivotal role in sequestering Ca<sup>2+</sup> into the ER, thereby maintaining low cytosolic Ca<sup>2+</sup> levels. Dysregulated SERCA function during ischemia contributes to ER Ca<sup>2+</sup> depletion, resulting in intracellular Ca<sup>2+</sup> imbalance and ER stress, both of which are implicated in the pathogenesis of ischemic reperfusion injury; SERCA has thus emerged as a potential pharmacological target for ischemic stroke. CDN1163, a SERCA activator, has shown promising effects in preclinical studies of neurodegenerative diseases by alleviating ER stress and restoring the Ca<sup>2+</sup> balance. This study investigates the neuroprotective potential of CDN1163 against cerebral ischemia-reperfusion (IR) injury using middle cerebral artery occlusion (MCAO) in rats. CDN1163 treatment (10 mg/kg, i.p.) significantly improved neurological scores, motor function, and behavior, while reducing infarct volume, brain edema, and oxidative stress by decreasing nitrite and lipid peroxidation and restoring glutathione levels. Histological analysis revealed reduced neuronal damage in the cortex, subcortex, and hippocampus regions. CDN1163 restored SERCA2b and 1a expression and mitigated ER stress by decreasing the expression of ER stress markers, such as PDI, BiP, p-IRE1α, XBP1, p-PERK, p-eIF2α, ATF4, and ATF6. Furthermore, CDN1163 downregulated pro-apoptotic markers Bax and CHOP, while upregulating the antiapoptotic protein Bcl-2 with TUNEL assay confirming decreased apoptosis. These outcomes highlight that CDN1163 is a potential therapeutic candidate for ischemic stroke, as it restores SERCA expression, alleviates endoplasmic reticulum stress, reduces oxidative stress, and inhibits apoptosis.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 9","pages":"2953–2963"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Calcium (Ca2+) homeostasis is critical for neuronal survival and function, which is regulated by a network of Ca2+-handling proteins. Among these, the sarco/endoplasmic reticulum calcium ATPase (SERCA) pump, located on the SR/ER membrane, plays a pivotal role in sequestering Ca2+ into the ER, thereby maintaining low cytosolic Ca2+ levels. Dysregulated SERCA function during ischemia contributes to ER Ca2+ depletion, resulting in intracellular Ca2+ imbalance and ER stress, both of which are implicated in the pathogenesis of ischemic reperfusion injury; SERCA has thus emerged as a potential pharmacological target for ischemic stroke. CDN1163, a SERCA activator, has shown promising effects in preclinical studies of neurodegenerative diseases by alleviating ER stress and restoring the Ca2+ balance. This study investigates the neuroprotective potential of CDN1163 against cerebral ischemia-reperfusion (IR) injury using middle cerebral artery occlusion (MCAO) in rats. CDN1163 treatment (10 mg/kg, i.p.) significantly improved neurological scores, motor function, and behavior, while reducing infarct volume, brain edema, and oxidative stress by decreasing nitrite and lipid peroxidation and restoring glutathione levels. Histological analysis revealed reduced neuronal damage in the cortex, subcortex, and hippocampus regions. CDN1163 restored SERCA2b and 1a expression and mitigated ER stress by decreasing the expression of ER stress markers, such as PDI, BiP, p-IRE1α, XBP1, p-PERK, p-eIF2α, ATF4, and ATF6. Furthermore, CDN1163 downregulated pro-apoptotic markers Bax and CHOP, while upregulating the antiapoptotic protein Bcl-2 with TUNEL assay confirming decreased apoptosis. These outcomes highlight that CDN1163 is a potential therapeutic candidate for ischemic stroke, as it restores SERCA expression, alleviates endoplasmic reticulum stress, reduces oxidative stress, and inhibits apoptosis.

Abstract Image

Sarco/内质网Ca2+- atp酶的小分子激活剂通过抑制内质网应激和细胞凋亡减轻脑缺血再灌注损伤
钙(Ca2+)稳态对神经元的存活和功能至关重要,这是由Ca2+处理蛋白网络调节的。其中,位于SR/ER膜上的sarco/endoplasmic reticulum calcium ATPase (SERCA)泵在将Ca2+隔离到ER中起关键作用,从而维持较低的胞质Ca2+水平。缺血时SERCA功能失调导致内质网Ca2+耗竭,导致细胞内Ca2+失衡和内质网应激,这两者都与缺血再灌注损伤的发病机制有关;因此,SERCA已成为缺血性卒中的潜在药理学靶点。CDN1163是一种SERCA激活剂,通过缓解内质网应激和恢复Ca2+平衡,在神经退行性疾病的临床前研究中显示出有希望的效果。本研究探讨CDN1163对大脑中动脉闭塞(MCAO)大鼠脑缺血再灌注(IR)损伤的神经保护作用。CDN1163治疗(10mg /kg, i.p)显著改善神经系统评分、运动功能和行为,同时通过减少亚硝酸盐和脂质过氧化和恢复谷胱甘肽水平减少梗死体积、脑水肿和氧化应激。组织学分析显示,皮层、皮层下和海马区的神经元损伤减少。CDN1163通过降低内质网应激标志物PDI、BiP、p-IRE1α、XBP1、p-PERK、p-eIF2α、ATF4和ATF6的表达,恢复SERCA2b和1a的表达,减轻内质网应激。此外,CDN1163下调促凋亡标志物Bax和CHOP,同时上调抗凋亡蛋白Bcl-2, TUNEL实验证实凋亡减少。这些结果强调CDN1163是缺血性卒中的潜在治疗候选者,因为它可以恢复SERCA表达,减轻内质网应激,减少氧化应激,抑制细胞凋亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Pharmacology and Translational Science
ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)
CiteScore
10.00
自引率
3.30%
发文量
133
期刊介绍: ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信